Q-omics provides the consensus-scored NANOS1 profile across patient tissues and cancer cell-line models. NANOS1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NANOS1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, NANOS1 RNA expression shows 19,171 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KICH, and UVM as cancer lineages where NANOS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOS1 survival associations across molecular data types. NANOS1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOS1 RNA expression–survival associations across cancer types. High NANOS1 expression shows unfavorable associations in BLCA, BRCA, KICH and ACC, but favorable associations in UCS and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for NANOS1 RNA expression.
This table summarizes NANOS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NANOS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOS1 shows lower tumor expression in KICH and KIRC and higher tumor expression in LUAD, LIHC, HNSC and LUSC. The KICH box plot shows higher NANOS1 RNA expression in normal versus tumor tissue (log2 FC = −2.267, t-test p < 0.001).
This table shows molecular features associated with NANOS1 in patient tissues and cancer cell lines. In patient samples, NANOS1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NANOS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
